Evaluation of a Novel MAGEC1 Variant and Susceptibility to Ovarian Cancer in the North Indian Population.

IF 1.1 4区 生物学 Q4 GENETICS & HEREDITY
Minerva Sharma, Sonali Verma, Vanshika Bhagat, Ziya Tufail, Rajeshwer Singh Jamwal, Bhawani Sharma, Gresh Chander, Ruchi Shah, Audesh Bhat, Manushi Dhar, Supinder Singh, Rakesh Kumar
{"title":"Evaluation of a Novel <i>MAGEC1</i> Variant and Susceptibility to Ovarian Cancer in the North Indian Population.","authors":"Minerva Sharma, Sonali Verma, Vanshika Bhagat, Ziya Tufail, Rajeshwer Singh Jamwal, Bhawani Sharma, Gresh Chander, Ruchi Shah, Audesh Bhat, Manushi Dhar, Supinder Singh, Rakesh Kumar","doi":"10.1089/gtmb.2025.0029","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> To check the correlation between the MAGE Family Member C1 (<i>MAGEC1)</i> gene variant rs176036 and ovarian cancer risk among the Jammu and Kashmir population. <b><i>Methodology:</i></b> A case-control association study of the <i>MAGEC1</i> gene variant rs176036 (G > A) and ovarian cancer. The variation was identified through whole exome sequencing, and the selected variant was genotyped in 111 patients with ovarian cancer and 107 healthy controls belonging to the Jammu and Kashmir region of North India using Sanger sequencing to confirm its association with the ovarian cancer. Odds ratio (OR) and other statistical values were calculated using standard tools. <b><i>Results:</i></b> The allelic frequency distribution was found to be similar between cases and controls, with the dominant allele (G) present in 89.6% of cases and 90.2% of controls (<i>p</i> = 0.84). The allelic OR for the dominant allele was 1.08 (0.55-2.11), which is nonsignificant (<i>p</i> = 0.83). <b><i>Conclusion:</i></b> The present study suggests that the rs176036 variant does not confer any increased risk of ovarian cancer among population of Jammu and Kashmir.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2025.0029","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To check the correlation between the MAGE Family Member C1 (MAGEC1) gene variant rs176036 and ovarian cancer risk among the Jammu and Kashmir population. Methodology: A case-control association study of the MAGEC1 gene variant rs176036 (G > A) and ovarian cancer. The variation was identified through whole exome sequencing, and the selected variant was genotyped in 111 patients with ovarian cancer and 107 healthy controls belonging to the Jammu and Kashmir region of North India using Sanger sequencing to confirm its association with the ovarian cancer. Odds ratio (OR) and other statistical values were calculated using standard tools. Results: The allelic frequency distribution was found to be similar between cases and controls, with the dominant allele (G) present in 89.6% of cases and 90.2% of controls (p = 0.84). The allelic OR for the dominant allele was 1.08 (0.55-2.11), which is nonsignificant (p = 0.83). Conclusion: The present study suggests that the rs176036 variant does not confer any increased risk of ovarian cancer among population of Jammu and Kashmir.

一种新的MAGEC1变异及其对北印度人群卵巢癌易感性的评估。
目的:探讨查谟和克什米尔地区人群MAGE家族成员C1 (MAGEC1)基因变异rs176036与卵巢癌风险的相关性。方法:MAGEC1基因变异rs176036 (G > A)与卵巢癌的病例对照相关性研究。通过全外显子组测序确定了该变异,并使用Sanger测序在印度北部查谟和克什米尔地区的111名卵巢癌患者和107名健康对照中进行了基因分型,以确认其与卵巢癌的关联。使用标准工具计算优势比(OR)和其他统计值。结果:病例和对照组的等位基因频率分布相似,显性等位基因G在病例中占89.6%,在对照组中占90.2% (p = 0.84)。显性等位基因OR为1.08(0.55 ~ 2.11),差异无统计学意义(p = 0.83)。结论:目前的研究表明rs176036变异不会增加查谟和克什米尔人群患卵巢癌的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
7.10%
发文量
63
审稿时长
1 months
期刊介绍: Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results. Genetic Testing and Molecular Biomarkers coverage includes: -Diagnosis across the life span- Risk assessment- Carrier detection in individuals, couples, and populations- Novel methods and new instrumentation for genetic testing- Results of molecular, biochemical, and cytogenetic testing- Genetic counseling
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信